Full-Time

Senior Quality Specialist

Globus Medical

Globus Medical

1,001-5,000 employees

Develops musculoskeletal implants and enabling technologies

No salary listed

Audubon, PA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Quality Assurance (QA)
Data Analysis
Excel/Numbers/Sheets

Get referred to Globus Medical

See people who can refer or advise you

Requirements
  • A Bachelor's Degree is required.
  • Experience performing file reviews and/or audits is required.
  • Quality assurance or quality control experience within the medical device, biotechnology, or another regulated industry is preferred.
  • Knowledge of Good Manufacturing Practice regulations is preferred.
  • Knowledge of Microsoft Word and Microsoft Excel is required.
  • Ability to evaluate and interpret technical data is required.
  • Ability to lift at least 25 pounds is required.
  • Strong typing, analytical, organizational, and problem-solving skills are required.
  • Excellent communication and writing skills are required.
  • Attention to detail is required.
  • Ability to work independently with minimal oversight is required.
Responsibilities
  • Support audit management.
  • Support electronic quality management system project management.
  • Support Document Control functions within a Product Life Cycle Management system.
  • Issue Quality System documents and coordinate the training process.
  • Release and maintain Quality Management System documents, including processing new documents and revision requests.
  • Ensure documentation is complete, properly formatted, and meets corporate standards.
  • Work with subject matter experts on gap analysis to ensure compliance with new and updated external standards.
  • Manage equipment maintenance and documentation, including calibrations and preventive maintenance.
  • Report non-conformances and discrepancies.
  • Generate Excel spreadsheets.
  • Participate in continuous improvement functions and implement changes for improvement.
  • Perform database searches, data analysis, and reporting as required.
  • Organize and communicate work status, objectives, and progress to management and other personnel.
  • Update and maintain the NetDimensions training system.
  • Maintain compliance with FDA Quality System Regulations, European Union regulations, and ISO 13485 requirements.
  • Complete required compliance training and maintain knowledge of applicable governmental laws, rules, and regulations.
  • Represent the company professionally and uphold ethical business practices in interactions with employees, customers, suppliers, and other third parties.
  • Perform other duties and responsibilities as necessary.
Desired Qualifications
  • Quality assurance or quality control experience within the medical device, biotechnology, or another regulated industry.
  • Knowledge of Good Manufacturing Practice regulations.

Globus Medical makes medical devices for musculoskeletal issues, especially spine, orthopedic, and neurosurgical care. Its products fall into two groups: Musculoskeletal Solutions with implantable devices, biologics, and surgical instruments, and Enabling Technologies with imaging, navigation, and robotics that help plan, guide, and analyze surgeries. The company stands out by offering an integrated platform that combines implants with enabling technologies to improve surgical precision and outcomes. Its goal is to help patients recover from musculoskeletal problems while expanding its product lines and geographic reach.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Lower Providence Township, Pennsylvania

Founded

2003

Get referred to Globus Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $789.6 million, beating estimates and rising 5.9% year over year.
  • Non-GAAP EPS hit $1.34 on 2026-08-06, and management raised full-year EPS guidance.
  • Share repurchases totaled $136.1 million in Q2 2026, signaling cash generation and confidence.

What critics are saying

  • Life Spine won the Federal Circuit on 2026-06-04, weakening Globus patent leverage.
  • FDA warning letter dated 2024-07-15 targeted ExcelsiusGPS complaint handling, MDR reporting, and CAPA.
  • Severe FDA action against ExcelsiusGPS freezes a high-margin platform and cuts Globus growth engine.

What makes Globus Medical unique

  • Globus Medical pairs spine implants, robotics, and patient-specific lumbar systems after Scripps clearances on 2026-08-06.
  • ExcelsiusGPS ties navigation, imaging, and robotics into one surgeon workflow across procedures.
  • NuVasive plus Nevro create a broader spine-and-pain platform than pure-play competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 7th, 2026
Globus Medical raises EPS guidance to $5.05 despite Nevro and Enabling Tech headwinds

Globus Medical reported second-quarter 2026 non-GAAP earnings per share of $1.34, beating the $1.12 consensus estimate. Revenue of $789.61 million also exceeded expectations of $786.86 million. The company raised full-year EPS guidance to $4.95-$5.05 from $4.70-$4.80 but maintained revenue guidance at $3.18-$3.22 billion. Second-quarter revenue grew 6% overall and 9% excluding Nevro, driven by 7% US Spine growth and 14% International Spine growth. Adjusted gross margin improved to 69.4%, up 200 basis points year-over-year. Adjusted EBITDA margin rose to 35.4% from 28.0%. Management cited Nevro and Enabling Technologies as potential risks to second-half performance. Enabling Technologies revenue fell 25.8% to $26.1 million as the company shifted towards flexible capital-acquisition options.

Associated Press
Aug 6th, 2026
Globus Medical Q2 sales hit $789.6M, non-GAAP EPS jumps 55.8% to $1.34

Globus Medical reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year-over-year, or 5.6% on a constant currency basis. GAAP diluted earnings per share fell 26.2% to $1.10, primarily due to a $110.5 million bargain purchase gain from the Nevro acquisition in the prior year quarter. However, non-GAAP diluted EPS rose 55.8% to $1.34. US spine sales grew 7%, whilst international spine sales increased 14% as-reported and 12% on a constant currency basis. Excluding Nevro, overall revenue growth was 9%. The musculoskeletal technology company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion. It raised its non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from the previous range of $4.70 to $4.80.

Yahoo Finance
Jul 21st, 2026
Globus Medical grows 27% as spine device maker raises guidance by 30 cents

Globus Medical reported strong first-quarter 2026 results, with revenue climbing 27% year-over-year to nearly $760 million and earnings per share rising to $1.12 from 68 cents, both exceeding analyst expectations. The $11 billion medical device company, which designs implantable devices and surgical instruments for spinal disorders, attributes growth to expanding market share, operational discipline, and dozens of new product launches. The company's US business has posted three consecutive quarters of at least 10% growth, whilst its international segment and enabling technologies division are also expanding. Following the strong performance, Globus raised its full-year EPS guidance by 30 cents to a range of $4.70-$4.80. The firm continues receiving FDA clearances to expand its product lineup.

Yahoo Finance
Jun 22nd, 2026
Globus Medical shares surge 5.1% after Q1 earnings beat estimates

Globus Medical shares rose 5.1% to $79.23 following strong first-quarter 2026 results. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both exceeding Zacks Consensus Estimates. The company is expected to report quarterly earnings of $1.12 per share in its upcoming report, representing a 30.2% year-on-year increase. Revenues are forecast at $787.34 million, up 5.6% from the previous year. The consensus EPS estimate has been revised 2.5% higher over the past 30 days. Globus Medical currently carries a Zacks Rank #2 (Buy). The stock has declined 10.3% over the past four weeks despite the recent surge.

Yahoo Finance
Jun 12th, 2026
Madison Small Cap Fund exits Globus Medical as $12B valuation surpasses intrinsic value estimate

Madison Small Cap Fund has sold its entire position in Globus Medical, Inc. (NYSE:GMED) after several years, citing valuation concerns as the company's market capitalisation reached $12 billion, according to its Q1 2026 investor letter. The fund sold at approximately $90 per share, above its intrinsic value estimate of $85. Globus Medical has successfully integrated its Nuvasive acquisition and continues strong adoption of its robotics platform. Madison said it will redirect capital towards smaller alternatives. In Q1 2026, Globus Medical generated revenue of $759.9 million, up 27% year-over-year. The company's market capitalisation now stands at $10.93 billion, with shares gaining 36.71% over the past 52 weeks. Hedge fund ownership increased to 52 funds in Q1 from 42 in the previous quarter.